Evidence map›Paper›PMID 23341016›Full record

ArticleInvestigative ophthalmology & visual science2013

Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations.

Alejandro J Roman, Artur V Cideciyan, Sharon B Schwartz, Melani B Olivares, Elise Heon, Samuel G Jacobson

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Pseudo-fovea formation after gene therapy for RPE65-LCA.Investigative ophthalmology & visual science · 2014
    Trial
  3. Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations inMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025
    Article
  4. Article
  5. Article
  6. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  7. Review
  8. Long-Term Follow-Up of Retinal Degenerations Associated WithTranslational vision science & technology · 2019
    Article
  9. Article
  10. Variability and Errors of Manually Digitized Goldmann Visual Fields.Optometry and vision science : official publication of the American Academy of Optometry · 2016
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Alejandro J RomanScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Artur V Cideciyan
Sharon B Schwartz
Melani B Olivares
Elise Heon
Samuel G Jacobson
University of Pennsylvania · USPenn Presbyterian Medical Center · USHospital for Sick Children · CA

Funding

Clinical Trials of Gene Therapy for Leber Congenital AmaurosisU10EY017280 · NEI · UNIVERSITY OF PENNSYLVANIA · PI JACOBSON, SAMUEL GREGORY · 2006 to 2014
$9.8M
NEI NIH HHS EY017280NEI NIH HHS U10 EY017280
6 · The paper itself

Abstract

purposeTo determine the intervisit variability of kinetic visual fields and visual acuity in patients with Leber congenital amaurosis (LCA) caused by mutations in the RPE65 (Retinal Pigment Epithelium-specific protein 65kDa) gene.

methodsRPE65-LCA patients (n = 20; ages 11-40 years) were studied on at least two visits separated by fewer than 120 days using Goldmann visual field (GVF) and ETDRS visual acuity (VA) in a retrospective review. GVFs were quantified by computing the spherical coordinates of their vertices and calculating the solid angle subtended, and reported in normalized solid-angle units (nsu) as a percentage of average normal field extent. Repeatability coefficients were calculated using 95% confidence intervals on log(10)-converted variables.

resultsVisual field extents in RPE65-LCA spanned a wide range from 4 to 95 nsu. The repeatability coefficient was 0.248 (log(10)nsu), suggesting cutoffs for significant change (in nsu) of +77% for improvement and -44% for worsening. VA in RPE65-LCA ranged from logMAR = 0.14 to 1.96 (20/40 to 20/1250). The repeatability coefficient was 0.170 (logMAR) (±8.5 ETDRS letters). Comparisons with published studies of ungenotyped retinitis pigmentosa showed that the RPE65-LCA patients had higher variability in kinetic field extent. VA variability in RPE65-LCA fell within reported results for retinitis pigmentosa.

conclusionsVariability data for GVF and VA are provided to permit interpretation of the significance of increases and decreases of these functional outcomes in ongoing and planned clinical trials of therapy for LCA caused by RPE65 mutations.

Indexed as

MutationAdolescentAdultChildcis-trans-IsomerasesDNADNA Mutational AnalysisElectroretinographyFemaleHumansLeber Congenital AmaurosisMalePhenotypeRetinaRetinoid IsomerohydrolaseRetrospective Studiescis-trans-IsomerasesDNARetinoid Isomerohydrolase

Identifiers

PMID23341016
PMCPMC3597193
OpenAlexW2004008278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.